Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine

Vaccine

Volumn 28, Issue 51, 2010, Pages 8169-8174

  Wang, Xuan Yi ^a   Zhang, Xin Xin ^b   Yao, Xin ^a   Jiang, Jie Hong ^b   Xie, You Hua ^a   Yuan, Zheng Hong ^a   Wen, Yu Mei ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Chronic Hepatitis B; HBeAg sero conversion; HBsAg; Immunogenic complex; Therapeutic vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SEROCONVERSION;

ADULT; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY; MALE; PLACEBOS; TREATMENT OUTCOME;

EID: 78649654354     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.093     Document Type: Article

References (39)

1. World Health Organization Hepatitis B 2009.
2. Milich D., Liang T.J. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003, 38(5):1075-1086.
3. Fontana R.J. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009, 49(Suppl. 5):S185-S195.
4. Ghany M.G., Doo E.C. Antiviral resistance and hepatitis B therapy. Hepatology 2009, 49(Suppl. 5):S174-S182.
5. Perrillo R., Tamburro C., Regenstein F., Balart L., Bodenheimer H., Silva M., et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995, 109(3):908-916.
6. Hui A.Y., Chan H.L., Cheung A.Y., Cooksley G., Sung J.J. Systematic review: treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005, 22(6):519-528.
7. Autran B., Carcelain G., Combadiere B., Debre P. Therapeutic vaccines for chronic infections. Science 2004, 305(5681):205-208.
8. Michel M.L. Towards immunotherapy for chronic hepatitis B virus infections. Vaccine 2002, 20(Suppl 4):A83-A88.
9. Xu D., Zhao K., Guo L., Li L., Xie Q., Ren H., et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 2008, 3(7):e2565.
10. Xu D.Z., Huang K.L., Zhao K., Xu L.F., Shi N., Yuan Z.H., et al. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 2005, 23(20):2658-2664.
11. Yao X., Zheng B., Zhou J., Xu D.Z., Zhao K., Sun S.H., et al. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007, 25(10):1771-1779.
12. Chan H.L., Wong V.W., Tse A.M., Tse C.H., Chim A.M., Chan H.Y., et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007, 5(12):1462-1468.
13. Manesis E.K., Hadziyannis E.S., Angelopoulou O.P., Hadziyannis S.J. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007, 12(1):73-82.
14. Wursthorn K., Lutgehetmann M., Dandri M., Volz T., Buggisch P., Zollner B., et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006, 44(3):675-684.
15. Habbema J., Eijkemans R., Krijnen P., Knottnerus J. Analysis of data on the accuracy of diagnostic tests. The evidence base of clinical diagnosis 2002, 117-144. BMJ Publishing Group, London. J. Knottnerus (Ed.).
16. Senturk H., Tabak F., Akdogan M., Erdem L., Mert A., Ozaras R., et al. Therapeutic vaccination in chronic hepatitis B. J Gastroenterol Hepatol 2002, 17(1):72-76.
17. Thermet A., Rollier C., Zoulim F., Trepo C., Cova L. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine 2003, 21(7-8):659-662.
18. Sprengers D., Janssen H.L. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005, 19(1):17-26.
19. Pol S., Michel M.L. Therapeutic vaccination in chronic hepatitis B virus carriers. Expert Rev Vaccines 2006, 5(5):707-716.
20. Chow Y.H., Chiang B.L., Lee Y.L., Chi W.K., Lin W.C., Chen Y.T., et al. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998, 160(3):1320-1329.
21. Davis H.L., McCluskie M.J., Gerin J.L., Purcell R.H. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci U S A 1996, 93(14):7213-7218.
22. Geissler M., Schirmbeck R., Reimann J., Blum H.E., Wands J.R. Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mice. Hepatology 1998, 28(1):202-210.
23. Saade F., Buronfosse T., Pradat P., Abdul F., Cova L. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes. Vaccine 2008, 26(40):5159-5164.
24. Fazle-Akbar S., Furukawa S., Onji M., Murata Y., Niya T., Kanno S., et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 2004, 29(3):136-141.
25. Jung M., Grüner N., Zachoval R., Schraut W., Gerlach T., Diepolder H., et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 2002, 20(29-30):3598-3612.
26. Pol S., Nalpas B., Driss F., Michel M., Tiollais P., Denis J., et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001, 34(6):917-921.
27. Wen Y.M., Wu X.H., Hu D.C., Zhang Q.P., Guo S.Q. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet Infect Dis 1995, 345(8964):1575-1576.
28. Wen Y. Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections. Expert Opin Biol Ther 2009, 9(3):285-291.
29. Wen Y.M., Qu D., Zhou S.H. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Int Rev Immunol 1999, 18(3):251-258.
30. Wang X.Y., Yao X., Guo L.M., Xu L.F., Shen X.L., Xu D.Z., et al. Advances on antigen-antibody immunogenic complex therapeutic vaccine for viral hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2009, 17(9):718-720.
31. McKee A.S., Munks M.W., MacLeod M.K., Fleenor C.J., Van Rooijen N., Kappler J.W., et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009, 183(7):4403-4414.
32. Kool M., Soullié T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205(4):869-882.
33. Aimanianda V., Haensler J., Lacroix-Desmazes S., Kaveri S.V., Bayry J. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 2009, 30(6):287-295.
34. Fattovich G., Giustina G., Sanchez-Tapias J., Quero C., Mas A., Olivotto P.G., et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998, 93(6):896-900.
35. Werle-Lapostolle B., Bowden S., Locarnini S., Wursthorn K., Petersen J., Lau G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004, 126(7):1750-1758.
36. Moucari R., Lada O., Marcellin P. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009, 7(6):633-636.
37. Perrillo R.P. Therapy of hepatitis B - viral suppression or eradication?. Hepatology 2006, 43(2 Suppl. 1):S182-S193.
38. Perrillo R.P. Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns. Hepatology 2009, 49(4):1063-1065.
39. Flink H.J., Sprengers S., Hansen B.E., van-Zonneveld M., de-Man R.A., Schalm S.W., et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during peg-interferon apha-2b therapy. Gut 2005, 54:1604-1609.